

Washington University School of Medicine Digital Commons@Becker

Open Access Publications

2018

Hemochromatosis (HFE) gene variants are associated with increased mitochondrial DNA levels during HIV-1 infection and antiretroviral therapy

Asha R. Kallianpur

Cleveland Clinic Lerner Research Institute

Mariana Gerschenson

University of Hawaii

Todd Hulgan

Vanderbilt University

Harpreet Kaur

Cleveland Clinic Lerner Research Institute

David B. Clifford

Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation

Kallianpur, Asha R.; Gerschenson, Mariana; Hulgan, Todd; Kaur, Harpreet; Clifford, David B.; Haas, David W.; Murdock, Deborah G.; McArthur, Justin C.; Samuels, David C.; and Simpson, David M., "Hemochromatosis (HFE) gene variants are associated with increased mitochondrial DNA levels during HIV-1 infection and antiretroviral therapy." *AIDS Research and Human Retroviruses*.34,11. 942-949. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7321

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Authors

Asha R. Kallianpur, Mariana Gerschenson, Todd Hulgán, Harpreet Kaur, David B. Clifford, David W. Haas, Deborah G. Murdock, Justin C. McArthur, David C. Samuels, and David M. Simpson

Hemochromatosis (*HFE*) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy

Asha R. Kallianpur,^{1,2} Mariana Gerschenson,³ Todd Hulgán,⁴ Harpreet Kaur,¹ David B. Clifford,⁵ David W. Haas,⁴ Deborah G. Murdock,⁶ Justin C. McArthur,⁷ David C. Samuels,⁸ and David M. Simpson⁹

Abstract

Some HIV-associated complications involve mitochondrial dysfunction and may be less common in individuals with iron-loading *HFE* (hemochromatosis gene) variants. We evaluated *HFE* 845A and 187G alleles in relation to mitochondrial DNA (mtDNA) levels in peripheral blood mononuclear cells from 85 individuals with HIV infection on uninterrupted antiretroviral therapy (ART) for 15 or more consecutive weeks. Carriers of *HFE* gene variants ($N=24$) had significantly higher mtDNA levels than noncarriers ($N=61$), after adjusting for age, race, sex, and type of ART [adjusted β -coefficient 297, p -value $< .001$ for at least one *HFE* variant], but mtDNA declined among all individuals on study during 48 weeks on ART. Increased cellular mtDNA content may represent a compensatory response to mitochondrial stress that is influenced by iron-loading *HFE* variants.

Keywords: allele, ART, *HFE*, mtDNA

Introduction

MITOCHONDRIAL DYSFUNCTION HAS long been associated with combination antiretroviral therapy (ART) in individuals with HIV infection and is implicated in the pathogenesis of ART-associated complications like peripheral neuropathy and lipodystrophy.¹ Antiretroviral mitochondrial toxicity includes, but may not be limited to, inhibition of mitochondrial DNA (mtDNA) synthesis by interference with mtDNA polymerase ($\text{pol-}\gamma$) activity (documented *in vitro*) and in turn, reduced transcription and translation of proteins essential for oxidative phosphorylation and cellular energy generation (the DNA $\text{pol-}\gamma$ hypothesis).²⁻⁴

In non-human primates, abnormal mitochondrial morphology and respiratory enzyme activity have been linked to nucleoside reverse-transcriptase inhibitor (NRTI)-associated mtDNA depletion.⁵ Accumulating evidence now indicates that the mitochondrial pathogenesis of many long-term complications of HIV infection in fact derives from multiple factors, not only

from the inhibition of mtDNA $\text{pol-}\gamma$. These factors include HIV infection itself, direct cytokine-mediated effects on mitochondria, and other antiretroviral drug effects on these organelles.⁶

Depletion of mtDNA, frequently studied in peripheral blood mononuclear cells (PBMCs), has been reported in HIV-seropositive (HIV+) individuals who are treated with NRTIs, particularly those exposed to dideoxy-NRTIs such as didanosine (ddI) or stavudine (d4T). Moreover, in ART-naive individuals with HIV, mtDNA depletion has been observed in both B and T cells; it correlates negatively with expression of immune-activation markers, and mtDNA levels in B cells correlate with the rate of CD4⁺ T-lymphocyte loss.^{7,8} The hierarchy of clinical NRTI toxicity parallels the degree of inhibition of DNA $\text{pol-}\gamma$ by these drugs.⁹ Early studies documenting the loss of mtDNA in PBMCs from treatment-naive individuals with HIV also suggested that direct effects of HIV on mitochondrial function and/or oxidative stress may be important and that these effects are further compounded by use of older, more mitochondria-toxic NRTIs.¹⁰ While the

¹Department of Genomic Medicine, Cleveland Clinic Foundation/Lerner Research Institute, Cleveland, Ohio.

²Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.

³Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii.

⁴Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

⁵Department of Neurology, Washington University in Saint Louis, St. Louis, Missouri.

⁶Children's Hospital of Philadelphia Research Institute & Center for Mitochondrial and Epigenomic Medicine, Philadelphia, Pennsylvania.

⁷Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.

⁸Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee.

⁹Icahn School of Medicine of Mount Sinai, New York, New York.

older and most toxic NRTIs are seldom used today, all NRTIs have some affinity for mtDNA pol- γ , and contemporary NRTIs also have measurable effects on mitochondrial function in clinical studies; even other classes of ART can have mitochondrial effects.^{11–13} Hence, it remains important to advance understanding of the basis of HIV- and ART-related mitochondrial dysfunction.

Iron is an essential micronutrient and cofactor for a large number of metabolic enzymes, and a steady supply of cellular iron is needed for normal mitochondrial function and cellular energy production. Accumulating evidence also suggests that mitochondrial function and mtDNA variants play a critical role in cellular iron homeostasis and inflammation.^{14–17} The HLA class I-like protein encoded by the hemochromatosis (*HFE*) gene affects macrophage function and inflammatory responses, partly by influencing hepatic synthesis of the master iron-regulatory, proinflammatory hormone, hepcidin. Hepcidin modulates systemic iron absorption and monocyte-macrophage iron content in response to a variety of inflammatory signals. Monocyte-macrophage iron content is important in oxidative microbial killing and may significantly influence proinflammatory cytokine production by cells of this lineage.^{18,19}

We previously reported associations of common variants in *HFE*, G845A and C187G, with a significantly reduced incidence of both peripheral sensory neuropathy and lipoatrophy during ART in AIDS Clinical Trials Group (ACTG) Study 384 participants.^{20,21} The mechanisms for those associations potentially include modulating effects of *HFE*-mediated increases in systemic iron levels on ART-induced mitochondrial toxicity. The objective of this study was to evaluate the impact of *HFE* variants on mtDNA content in PBMCs among persons who were receiving chronic, uninterrupted ART that included antiretrovirals with known mitochondrial toxicity.

Methods

Study design and subject selection

DNA samples and linked clinical data for this nested case-control analysis were collected from 87 participants in ACTG protocol A5117 (NCT00017771), in whom mtDNA copy number per cell measurements was available and who also provided DNA for genetic studies. ACTG Study A5117 was a prospective, multicenter, observational cohort study of peripheral neuropathy in HIV infection, which enrolled individuals with HIV infection between October 2001 and June 2002 at participating sites of the ACTG and Neurologic AIDS Research Consortium (NARC) with neurological expertise.²² All subjects provided written informed consent, and the institutional review boards of all participating centers approved the study. Eligible subjects were 13 years of age and older with advanced HIV disease, as evidenced by a CD4⁺ T-lymphocyte count <300 cells/mm³, and at least 15 consecutive weeks of ART exposure. Of note, individuals with conditions other than HIV infection or a history of ART that might confound the diagnosis of neuropathy related to ART were excluded. Detailed inclusion/exclusion criteria and study procedures for ACTG study A5117 were previously published.²²

Genotyping and mtDNA measurements

Whole-blood samples were collected at study entry and at 48 weeks on study in a 10-mL acid citrate dextrose tube

(Becton Dickinson, San Jose, CA), and lymphocytes were isolated by Ficoll gradient centrifugation. Total genomic DNA was extracted from blood-derived lymphocytes [QIAamp DNA Blood Mini kit and DNeasy Tissue kit, both from Qiagen, Inc., Valencia, CA]. *HFE* genotypes at the two most commonly polymorphic loci, 845G>A, or G845A (rs1800562) and 187C>G, or C187G (rs1799945), were determined using the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems) and customized TaqMan assays, as reported elsewhere.²⁰

Dry pellets of lymphocytes (1×10^7 cells) were stored at -70°C . Total DNA was assayed for mtDNA using mitochondrial primers that amplify a 90-bp region of mtDNA encoding NADH dehydrogenase subunit 2, and genomic DNA primers specific for the region encoding Fas ligand (98 bp), by real-time PCR, using published PCR cycling conditions. The PCR reactions were assayed with the Lightcycler FastStart DNA Master SYBR Green I mix in the LightCycler real-time instrument (Roche Diagnostic Corporation, Indianapolis, IN). Each sample and standard were run in duplicate (20- μL reaction volume containing $1 \times$ SYBR Green master mix, 0.5 μM of each primer, and 10 ng of nuclear [genomic] DNA [nDNA]). Results were analyzed with LightCycler Version 4.0 software. The number of mtDNA copies per cell was calculated using the following formula: (mtDNA copies/nDNA copies) \times 2 = mtDNA copies per cell.²³ All mtDNA/nDNA measurements for this analysis were performed by a single laboratory, eliminating the intersite assay variability that has previously been reported.²⁴

Statistical analyses

The distribution of variables at entry onto the study was compared between *HFE* genotype categories by the Student's *t*-test or Mann–Whitney U test (continuous variables), or by the chi-square or Fisher's exact test (categorical variables). Unadjusted analyses of mtDNA copies per cell at entry and at 48 weeks of observation were performed using the non-parametric Mann–Whitney U test, because this variable was not normally distributed, and results were stratified by self-reported race/ethnicity and *HFE* genotype. Multivariable analyses of the association between *HFE* genotype and mtDNA copies per cell at entry, mtDNA copies per cell at 48 weeks, and the change in mtDNA copies per cell over 48 weeks on study were performed by multiple linear regression, adjusting for age, race/ethnicity, sex, ddI use, total dideoxy-NRTI drug (d-drug) use [0 vs. ≥ 1 d-drug at entry], CD4⁺ T-lymphocyte count, and HIV RNA concentration at study entry. STATA statistical software version 10.0 was used for all analyses (Stata Corp LP, College Station, TX).

Results

Baseline demographic and clinical characteristics of study subjects are shown in Table 1. The mean age of HIV+ persons was 37 ± 9 years, 8 (9%) were women, and 39% were non-white. This population had advanced HIV disease, with a mean CD4⁺ T-cell count of 165 per mm³ and a median HIV RNA concentration in plasma (viral load) of 2.9 log₁₀ (copies per mL). Treatment regimens at study entry included ddI in 22%, d4T in 33%, and zalcitabine (ddC) in 1.1% of subjects, and median cumulative ddI exposure was 1.4 years (range 0–6.6 years). Use of at least one NRTI drug was reported at the

TABLE 1. CHARACTERISTICS OF A5117 STUDY PARTICIPANTS AT ENTRY

Characteristic at study entry	<i>All participants</i>	<i>No HFE variant alleles^a</i>	<i>≥1 variant HFE allele(s)^a</i>
	N = 87	N = 61	N = 24
Age			
Mean ± SD	37 ± 9	37 ± 9	36 ± 9
Race (% non-whites)	39	51	14 ^b
Sex (% women)	9	11	8
CD4 ⁺ T cells/mm ³ mean ± SD	165 ± 93	156 ± 95	177 ± 84
HIV RNA concentration			
log ₁₀ [Copies/mL] median (range)	2.9 (2.2–5.8)	3.4 (2.2–5.8)	2.9 (2.2–5.6)
ddI use (%)	22	16	29
d4T use (%)	33	36	25
ddC use (%)	1.1	1.6	0
Cumulative ddI use ^c			
Median years (range)	1.4 (0–6.6)	1.5 (0–6.6)	1.4 (0.1–3.7)
Total NRTI use (% on ≥1 NRTI)	94	95	92
Total PI use (% on ≥1 PI)	69	72	67
NNRTI use (%)	37	38	33
Alcohol use (%)	65	68	56

^aTwo individuals could not be genotyped at the *HFE* G845A or C187G loci.

^bOnly self-reported race differed significantly by *HFE* genotype ($p < .01$).

^cInformation on cumulative d-drug use was available in only 45% of individuals; p -value for comparison of ancestral versus variant *HFE* allele categories was not statistically significant.

HFE, hemochromatosis 845A and/or 187G variant allele(s); SD, standard deviation; ddI, didanosine; d4T, stavudine; ddC, dideoxycytosine; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nucleoside reverse-transcriptase inhibitor; PI, protease inhibitor.

baseline visit in 82 (94%) and protease inhibitor use in 60 individuals (69%); prevalence of non-NRTI (NNRTI) use was 37%. Median cumulative exposure to other d-drugs in the study sample was 2.1 years for d4T (63 individuals, range 0–7.2 years) and 10 months for ddC (15 individuals, range 2 months to 5.2 years); however, data on the duration of all prior ART among participants on ART at entry were not available.

Among 87 study participants with available DNA and mtDNA copies per cell measurements, *HFE* G845A and C187G genotypes were successfully determined in 85 (98%); there were no G845A or C187G homozygotes, eight 845GA heterozygotes, 16 C187CG heterozygotes, and no compound heterozygotes. Occasional or frequent alcohol use was reported by 65% of participants and was similar in both genotype groups. Carriers of one variant *HFE* allele (187G or 845A) were not significantly different from HIV+ individuals

with neither *HFE* variant (noncarriers) with respect to age, sex, and other baseline characteristics (including individual d-drug and cumulative ddI use), except for race/ethnicity. As anticipated from the known racial distribution of the *HFE* variants studied, individuals with *HFE* variant alleles were significantly more likely than noncarriers to be white (86% vs. 49%, $p < .01$).

Results of unadjusted analyses of mtDNA copies per cell at baseline in subjects with and without *HFE* variants are shown in Table 2. Median mtDNA content at entry in PBMCs was significantly higher among all 24 subjects with at least one *HFE* variant than among the 61 individuals with ancestral alleles at both *HFE* loci [668 (interquartile range, IQR 324, 954) vs. 396 (IQR 274, 537) copies per cell, respectively; $p = .01$]. Similarly, significant differences were observed in whites [median mtDNA copies per cell of 613 (IQR 335, 897)

TABLE 2. UNADJUSTED ANALYSIS OF MTDNA COPY NUMBER PER CELL IN PERIPHERAL BLOOD LYMPHOCYTES AT ENTRY IN SUBJECTS WITH AND WITHOUT *HFE* GENE VARIANTS


Variable	N	<i>No variant HFE alleles</i>	N	<i>≥1 variant HFE allele(s)</i>	p-value
		Median (IQR)		Median (IQR)	
All participants					
MtDNA copy number at BL	61	396 (274, 537)	24	668 (324, 954)	.01
Change in mtDNA copy number, BL to 48 weeks (% change) ^a	53	−108 (−187, 53) −19%	20	−314 (−662, −3) −47%	.08
Whites					
MtDNA copy number at BL	30	344 (231, 447)	21	613 (335, 897)	.03
Change in mtDNA copy number, BL to 48 weeks (% change)	20	−116 (−211, 70) −25%	16	−314 (−662, 3) −47%	.15

p -values $< .05$ are considered statistically significant.

^aLongitudinal mtDNA copy number data were available in 86% of participants.

HFE, hemochromatosis gene; mtDNA, mitochondrial DNA; IQR, interquartile range; BL, baseline.

FIG. 1. Mitochondrial DNA copy number per cell at entry and 48 weeks, stratified by *HFE* genotype status. *HFE*, hemochromatosis gene.



copies per cell among 21 carriers of *HFE* variant alleles vs. 344 copies per cell (IQR 231, 447) among 30 noncarriers, $p = .03$]. Median mtDNA copy number per cell was significantly higher in carriers than in noncarriers of *HFE* variant alleles among whites ($p = .03$). The median absolute change in within-individual mtDNA copies per cell from study entry (baseline) to 48 weeks on ART was also greater for subjects with *HFE* gene variants in the entire study sample, although this difference did not reach statistical significance [-314 (IQR $-662, -3$) in individuals with at least one variant vs. -108 (IQR $-187, 53$) in individuals with only ancestral *HFE* alleles, corresponding to -47% vs. -19% percent change, respectively ($p = .08$)].

Figure 1 summarizes mtDNA copy numbers at entry and 48 weeks, stratified by *HFE* genotype status. The decline in PBMC mtDNA content was also nonsignificantly greater among whites with *HFE* variants compared to those without *HFE* variants [median -314 (IQR $-662, 3$) vs. -116 ($-211, 70$), $p = .15$], corresponding to a -47% and -25% change, respectively. MtDNA copy number per cell was nonsignificantly higher at baseline in participants with *HFE* 845A or 187G alleles, when these alleles were evaluated separately, but the number of individuals with *HFE* 845A alleles was very small; differences between 187G carriers and noncarriers approached statistical significance ($p = .07$, Table 3).

Protease inhibitor use, mitochondrial haplogroup T status (previously linked to NRTI-associated mitochondrial toxicities), and d4T and ddC use at baseline were not significantly

associated with either mtDNA copies per cell or with the presence of *HFE* variants (*some of these data not shown*), and were therefore not included individually as covariates in multivariable regression models; however, ddI use and the total number of NRTIs used were included. MtDNA copies per cell in study participants at baseline were not associated with $CD4^+$ T-cell count or HIV RNA concentration in plasma.

Multivariable regression analyses revealed that *HFE* variant alleles were independently associated with greater PBMC mtDNA content at baseline (β -coefficient 297, $p < .001$) in this extensively ART-treated population, adjusting for age, self-reported race/ethnicity, sex, and the following variables: total NRTI drug use, ddI use, $CD4^+$ T-cell count, and plasma HIV RNA concentration (results presented in Table 4). Associations of mtDNA copy number with ddI use and with total NRTI use tended toward statistical significance [β -coefficients -165 ($p = .05$) and 67 ($p = .08$), respectively], whereas no associations were observed with $CD4^+$ T-cell count or plasma viral load (β -coefficients -0.42 ($p = .26$) and -36 ($p = .20$), respectively].

TABLE 3. MITOCHONDRIAL DNA CONTENT IN PERIPHERAL BLOOD LYMPHOCYTES AT BASELINE BY *HFE* GENOTYPE

<i>HFE</i> genotype	N	MtDNA copy number at BL Median (IQR)	p-value
845GG	77	401 (284, 636)	.27
845GA	8	632 (324, 844)	
187CC	69	403 (282, 604)	.07
187CG	16	608 (335, 1010)	

Unadjusted p -values for comparison of mtDNA copy number by *HFE* *G845A* and *C187G* genotype are shown. p -values $< .05$ are considered statistically significant.

TABLE 4. RESULTS OF MULTIVARIABLE-ADJUSTED REGRESSION MODEL OF mtDNA COPY NUMBER PER CELL IN ALL A5117 STUDY PARTICIPANTS AT ENTRY

Variable in model	β -Coefficient (95% CI)	p-value
≥ 1 <i>HFE</i> variant allele (845A, 187G, or both)	297 (142–452)	$< .001$
Age	0.50 (-7.0 to 8.0)	.90
Race (self-report)	-75 (-220 to 70)	.30
Sex	-42 (-228 to 143)	.65
ddI use	-165 (-332 to 2.1)	.05
Total NRTI use	67 (-8.0 to 141)	.08
$CD4^+$ T cells/mm ³	-0.42 (-1.2 to 0.32)	.26
HIV RNA concentration (plasma)	-36 (-91 to 19)	.20

For each factor in the model, the estimate of association with mtDNA copy number [β -coefficient, 95% confidence interval (95% CI)] is shown; p -values $< .05$ are statistically significant.

A stratified analysis among 51 self-described white participants was also performed, since *HFE* variants are considerably more prevalent in whites, and the results of this analysis were similar. Median mtDNA copy number per cell at baseline was 613 (IQR 335, 897) among white individuals with *HFE* variants (845A or 187G), compared to 344 (IQR 231, 447) in noncarriers of these variants ($p < .05$).

Discussion

This study evaluated potential associations between PBMC mtDNA content and common *HFE* G845A and C187G missense variants. Importantly, susceptibility to the mitochondrial toxicities of ART is still relevant in the modern ART era: antiretroviral drugs with mitochondrial effects continue to be used in low-resource settings due to their lower cost, and the possibility of subclinical mitochondrial toxicity during treatment with antiretrovirals other than the dideoxy-NRTIs remains an open question.^{25,26} Previous studies have documented both increases and decreases in mtDNA levels as a physiological response to mitochondrial stress^{27–31} and *HFE* variants have been associated with elevated urinary levels of F₂-isoprostanes (a specific marker of *in vivo* oxidative injury),³² as well as with indicators of increased mitochondrial stress,^{33,34} such as reduced mitochondrial membrane potential. This study represents the first report of an independent association of *HFE* variant genotype with increased mtDNA copies per cell in PBMCs from individuals with HIV on ART.

The NRTI drug class is known to inhibit mtDNA polymerase- γ , and mtDNA depletion could play an important role in mediating or promoting mitochondrial toxicities in clinical practice.^{6,35} The finding that mtDNA copies per cell during ART decreased over the course of follow-up for all participants, regardless of *HFE* genotype, provides confirmatory evidence of ART-mediated mitochondrial stress. Responses to this stress may, in turn, be influenced by changes in iron transport or other downstream effects of *HFE* variants, such as altered macrophage-mediated inflammation.³⁶ The impact of *HFE* variants on the risk of neuropathy and other mitochondrial sequelae of ART may therefore be influenced by a combination of *HFE*-mediated changes in systemic iron levels, cellular iron transport, and cellular mtDNA content.

Prior work has shown that individuals heterozygous at the *HFE* locus have increased systemic levels of iron, as well as oxidatively active (non-transferrin bound and labile) forms of iron, and they experience higher levels of oxidative stress.^{37–40} Hence, it would not have been surprising to find that *HFE* variants increased the risk of mitochondrial toxicities in individuals with HIV. To the contrary, we previously reported the association between *HFE* variant G845A (Cys282Tyr) and a decreased risk of NRTI-associated peripheral neuropathy in ACTG study 384.²¹ The more prevalent polymorphism C187G (His63Asp) is also associated with higher systemic iron indices and was associated with reduced risk of neuropathy among whites in univariate, but not in multivariable-adjusted analyses. The 187G SNP was also significantly associated with a reduced risk of lipoatrophy, another ART-associated mitochondrial toxicity.²⁰ A possible explanation for these associations is that increased mtDNA synthesis occurs as a physiological response to mitochondrial stress or toxicity during ART in individuals with higher iron stores, as iron is essential for normal mitochondrial function and energy me-

tabolism, and iron metabolism and mitochondrial metabolism are coordinately regulated.^{41–44}

Considerable evidence supports the depletion of mtDNA content in HIV- and ART-related comorbidities, such as lipoatrophy, diabetes mellitus and other metabolic disorders, increased risk of cardiovascular and hepatic disease, and accelerated aging.^{25,45–47} In addition, it has also been reported that pregnant women with HIV have significantly lower mtDNA/nDNA ratios than pregnant women without HIV infection after controlling for platelet count, raising the possibility that lower levels of maternal mtDNA due to HIV infection, ART, or both, could exert long-term health effects in their children.⁴⁸ Studies to better understand and elucidate mechanisms underlying these changes will therefore also help to optimize the safety of ART regimens used during pregnancy. Several older studies found that HIV+, ART-naive persons had higher mtDNA-to-nDNA ratios than did ART-exposed persons, and that discontinuing ART (in particular, d-drugs with known mitochondrial toxicity) led to a statistically significant increase in this ratio.^{49–52} On the other hand, Maagaard *et al.* 2006 reported that mtDNA copies per cell in PBMCs did not differ between treatment-naive and NRTI-exposed persons, while individuals with HIV had significantly lower values than HIV-negative controls; lactate/pyruvate ratios were also higher in individuals with HIV.⁷

HFE gene variants are much less prevalent in non-European-ancestry populations, suggesting another reason for the higher risk of ART-associated neuropathy (and possibly also other mitochondrial toxicities) among African Americans, which has been reported by some investigators.⁵³ However, it is important to note that despite the association with higher mtDNA content at baseline, *HFE* variant allele carriers also experienced greater declines in mtDNA copies per cell during the first 48 weeks of ART. Such effects suggest that *HFE* gene variants lead to either increased cellular mtDNA synthesis or increased numbers of mitochondria in PBMCs in the short term, which may protect against antiretroviral drug toxicity. However, these adaptations may not be sustainable during long-term ART and may ultimately augment mitochondrial stress and mtDNA depletion. Replication of these observations in other populations with HIV and further exploration of the mechanisms by which *HFE* exerts these effects are needed.

A limitation of our study is that we did not directly measure blood iron levels in study participants, although the published literature is relatively consistent in associating higher systemic iron stores, as reflected by levels of serum iron, transferrin saturation, and/or ferritin, with the presence of *HFE* variants.^{54,55} A comparison group of otherwise similar individuals without HIV was also not available for mtDNA copy number measurements, so the individual contributions of *HFE* variants and HIV infection to mtDNA content in PBMCs could not be differentiated in this study. We did not include cumulative ddI exposure, or information about changes in d-drug exposure over the course of the study, as covariates in multivariable regression models, because this information was not available in a substantial proportion of individuals; similarly, data on cumulative exposure to all d-drugs were not available. Importantly, however, cumulative ddI exposure did not differ by *HFE* genotype, and we did adjust for ddI use at the time of blood sampling and for the total number of NRTIs, including d-drugs, that were used.

Furthermore, in the primary analyses of these data, Simpson *et al.* (2006) found that neither d-drug antiretroviral use at baseline nor cumulative d-drug use was associated with total neuropathy score, arguing against a confounding effect by cumulative d-drug or NRTI use in this analysis.²² Indeed, a growing number of genetic studies suggest that HIV infection, even in ART-naive individuals, may result in mitochondrial dysfunction and reduced cellular mtDNA content.²⁵ While no clear mechanism for this observation has yet emerged, our findings suggest that altered mtDNA biogenesis as a result of ART-induced disruption of cellular iron transport may contribute to this mitochondrial damage.⁵⁶

Additional studies are needed to investigate the role of *HFE* variants as well as systemic iron status and mtDNA copies per cell in mitochondrial toxicities of HIV infection and ART, in monitoring of disease severity during treatment, and in choice of treatment regimen. However, the findings reported in this study support the concept that iron metabolism and individual genetic variation in cellular iron transport significantly impact mtDNA levels and constitute one mechanism by which neurological complications in persons with HIV, due either to HIV disease itself or the effects of ART, may be influenced by host genetics.

Acknowledgments

We are deeply grateful to all study volunteers who participated in ACTG Study 384 and protocol A5117. We also wish to thank all of the ACTG clinical sites where participants were enrolled and followed, as well as the ACTG and the A5117 protocol team. Finally, we thank Cara Sutcliffe and Ping Mayo in the Vanderbilt Center for Human Genetics Research (DNA Core Laboratory) for genotyping assistance.

Funding support for these analyses was provided by NHLBI R21HL087726-03 (to AK), NIH 1P20GM113134 and 2 U54MD007601 (to MG), and NIH R21NS059330 (to TH).

The primary A5117 protocol was supported by the NIAID, AI38858, AI03855, AI25903, AI27664, AI046376, AI34853, AI27658, AI27670, AI46386, AI-25859, AI46370, AI32770, and AI27668, and the Neurologic AIDS Research Consortium funded by the National Institute of Neurologic Diseases and Stroke, NS032228, NS44807, and K24 NS002253 (DMS), and GCRC Units funded by the NCRR, RR00522, RR016467, RR00044, RR-00071, and RR00051.

Research reported in this publication was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number UM1 AI068634, UM1 AI068636, and UM1 AI106701. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author Disclosure Statement

No competing financial interests exist.

References

- Gardner K, Hall PA, Chinnery PF, Payne BA: HIV treatment and associated mitochondrial pathology: Review of 25 years of in vitro, animal, and human studies. *Toxicol Pathol* 2014;42:811–822.
- Lewis W, Day BJ, Copeland WC: Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. *Nat Rev Drug Discov* 2003;2:812–822.
- Margolis AM, Heverling H, Pham PA, Stolbach A: A review of the toxicity of HIV medications. *J Med Toxicol* 2014;10:26–39.
- Apostolova N, Blas-Garcia A, Esplugues JV: Mitochondrial toxicity in HAART: An overview of in vitro evidence. *Curr Pharm Des* 2011;17:2130–2144.
- Dagan T, Sable C, Bray J, Gerschenson M: Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence? *Mitochondrion* 2002;1:397–412.
- Gerschenson M, Brinkman K: Mitochondrial dysfunction in AIDS and its treatment. *Mitochondrion* 2004;4:763–777.
- Maagaard A, Holberg-Petersen M, Kvittingen EA, Sandvik L, Bruun JN: Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. *HIV Med* 2006;7:53–58.
- Maagaard A, Holberg-Petersen M, Lovgarden G, Holm M, Pettersen FO, Kvale D: Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment. *J Infect Dis* 2008;198:1474–1481.
- Kallianpur AR, Hulan T: Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy. *Pharmacogenomics* 2009;10:623–637.
- McComsey GA, Paulsen DM, Lonergan JT, *et al.*: Improvements in lipotrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. *AIDS* 2005;19:15–23.
- Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. *Biochemistry* 2003;42:14711–14719.
- McComsey GA, Daar ES, O’Riordan M, *et al.*: Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202. *J Infect Dis* 2013; 207:604–611.
- Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N: Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. *J Antimicrob Chemother* 2015;70:2249–2254.
- Richardson DR, Lane DJ, Becker EM, *et al.*: Mitochondrial iron trafficking and the integration of iron metabolism between the mitochondrion and cytosol. *Proc Natl Acad Sci U S A* 2010;107:10775–10782.
- Levi S, Rovida E: The role of iron in mitochondrial function. *Biochim Biophys Acta* 2009;1790:629–636.
- Urrutia PJ, Mena NP, Nunez MT: The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. *Front Pharmacol* 2014;5:38.
- Atilano SR, Malik D, Chwa M, *et al.*: Mitochondrial DNA variants can mediate methylation status of inflammation, angiogenesis and signaling genes. *Hum Mol Genet* 2015; 24:4491–4503.
- Gaetano C, Massimo L, Alberto M: Control of iron homeostasis as a key component of macrophage polarization. *Haematologica* 2010;95:1801–1803.

19. Habib A, Finn AV: The role of iron metabolism as a mediator of macrophage inflammation and lipid handling in atherosclerosis. *Front Pharmacol* 2014;5:195.
20. Hulgán T, Tebas P, Canter JA, *et al.*: Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipotrophy during antiretroviral therapy. *J Infect Dis* 2008;197:858–866.
21. Kallianpur AR, Hulgán T, Canter JA, *et al.*: Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. *AIDS* 2006;20:1503–1513.
22. Simpson DM, Kitch D, Evans SR, *et al.*: HIV neuropathy natural history cohort study: Assessment measures and risk factors. *Neurology* 2006;66:1679–1687.
23. Shiramizu B, Shikuma KM, Kamemoto L, *et al.*: Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. *J Acquir Immune Defic Syndr* 2003;32:370–374.
24. Cote HC, Gerschenson M, Walker UA, *et al.*: Quality assessment of human mitochondrial DNA quantification: MITONAUTS, an international multicentre survey. *Mitochondrion* 2011;11:520–527.
25. Hulgán T, Gerschenson M: HIV and mitochondria: More than just drug toxicity. *J Infect Dis* 2012;205:1769–1771.
26. Kallianpur AR, Wang Q, Jia P, *et al.*: Anemia and red blood cell indices predict HIV-associated neurocognitive impairment in the highly active antiretroviral therapy era. *J Infect Dis* 2016;213:1065–1073.
27. Kang D, Hamasaki N: Mitochondrial oxidative stress and mitochondrial DNA. *Clin Chem Lab Med* 2003;41:1281–1288.
28. Durham SE, Samuels DC, Cree LM, Chinnery PF: Normal levels of wild-type mitochondrial DNA maintain cytochrome c oxidase activity for two pathogenic mitochondrial DNA mutations but not for m.3243A→G. *Am J Hum Genet* 2007;81:189–195.
29. Chinnery PF, Samuels DC: Relaxed replication of mtDNA: A model with implications for the expression of disease. *Am J Hum Genet* 1999;64:1158–1165.
30. Stewart JD, Schoeler S, Sitarz KS, *et al.*: POLG mutations cause decreased mitochondrial DNA repopulation rates following induced depletion in human fibroblasts. *Biochim Biophys Acta* 2011;1812:321–325.
31. Sitarz KS, Yu-Wai-Man P, Pyle A, *et al.*: MFN2 mutations cause compensatory mitochondrial DNA proliferation. *Brain* 2012;135(Pt 8):e219, 211–213. author reply: e220, 211–213.
32. Kom GD, Schwedhelm E, Nielsen P, Boger RH: Increased urinary excretion of 8-iso-prostaglandin F2alpha in patients with HFE-related hemochromatosis: A case-control study. *Free Radic Biol Med* 2006;40:1194–1200.
33. Lee SY, Patton SM, Henderson RJ, Connor JR: Consequences of expressing mutants of the hemochromatosis gene (HFE) into a human neuronal cell line lacking endogenous HFE. *FASEB J* 2007;21:564–576.
34. Mairuae N, Hall I EC, Cheepsunthorn P, Lee SY, Connor JR: The H63D HFE gene variant promotes activation of the intrinsic apoptotic pathway via mitochondria dysfunction following beta-amyloid peptide exposure. *J Neurosci Res* 2010;88:3079–3089.
35. McComsey GA, Libutti DE, O’Riordan M, *et al.*: Mitochondrial RNA and DNA alterations in HIV lipotrophy are linked to antiretroviral therapy and not to HIV infection. *Antivir Ther* 2008;13:715–722.
36. Mitchell RM, Lee SY, Randazzo WT, Simmons Z, Connor JR: Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1. *J Neuroinflamm* 2009;6:6.
37. Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP: Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. *N Engl J Med* 1996;335:1799–1805.
38. Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck BS, Marx JJ: Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human serums. *FASEB J* 2006;20:353–355.
39. Pulliam JF, Jennings CD, Kryscio RJ, *et al.*: Association of HFE mutations with neurodegeneration and oxidative stress in Alzheimer’s disease and correlation with APOE. *Am J Med Genet B Neuropsychiatr Genet* 2003;119B:48–53.
40. Sanguuolo F, Puxeddu E, Pezzuto G, *et al.*: HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. *Eur Respir J* 2015;45:483–490.
41. Rensvold JW, Ong SE, Jeevananthan A, Carr SA, Mootha VK, Pagliarini DJ: Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis. *Cell Rep* 2013;3:237–245.
42. Feder JN, Gnirke A, Thomas W, *et al.*: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet* 1996;13:399–408.
43. Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK: A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. *Gastroenterology* 2002;122:646–651.
44. Whitfield JB, Cullen LM, Jazwinska EC, *et al.*: Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. *Am J Hum Genet* 2000;66:1246–1258.
45. De Wit S, Sabin CA, Weber R, *et al.*: Incidence and risk factors for new-onset diabetes in HIV-infected patients: The data collection on adverse events of Anti-HIV Drugs (D:A:D) study. *Diabetes Care* 2008;31:1224–1229.
46. Waters L, Nelson M: Long-term complications of antiretroviral therapy: Lipotrophy. *Int J Clin Pract* 2007;61:999–1014.
47. Caron-Debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J: HIV-associated lipodystrophy: From fat injury to premature aging. *Trends Mol Med* 2010;16:218–229.
48. Money DM, Wagner EC, Maan EJ, *et al.*: Evidence of subclinical mtDNA alterations in HIV-infected pregnant women receiving combination antiretroviral therapy compared to HIV-negative pregnant women. *PLoS One* 2015;10:e0135041.
49. Cote HC, Brumme ZL, Craib KJ, *et al.*: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. *N Engl J Med* 2002;346:811–820.
50. Montaner JS, Cote HC, Harris M, *et al.*: Mitochondrial toxicity in the era of HAART: Evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. *J Acquir Immune Defic Syndr* 2003;34;Suppl 1:S85–S90.
51. Chiappini F, Teicher E, Saffroy R, *et al.*: Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated

- or HAART-treated HIV-positive patients. *Lab Invest* 2004; 84:908–914.
52. Montaner JS, Cote HC, Harris M, *et al.*: Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: Insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. *Clin Infect Dis* 2004;38;Suppl 2:S73–S79.
53. Anziska Y, Helzner EP, Crystal H, *et al.*: The relationship between race and HIV-distal sensory polyneuropathy in a large cohort of US women. *J Neurol Sci* 2012;315:129–132.
54. Jones NR, Ashmore JH, Lee SY, Richie JP, Lazarus P, Muscat JE: Association studies of HFE C282Y and H63D variants with oral cancer risk and iron homeostasis among whites and blacks. *Cancers (Basel)* 2015;7:2386–2396.
55. Gallego CJ, Burt A, Sundaresan AS, *et al.*: Penetrance of Hemochromatosis in HFE genotypes resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network. *Am J Hum Genet* 2015;97:512–520.
56. Costantini A, Giuliodoro S, Butini L, Silvestri G, Leoni P, Montroni M: Abnormalities of erythropoiesis during HIV-1 disease: A longitudinal analysis. *J Acquir Immune Defic Syndr* 2009;52:70–74.

Address correspondence to:

Asha R. Kallianpur

Department of Genomic Medicine

Cleveland Clinic Foundation/Lerner Research Institute

9500 Euclid Avenue/Mail Code NE50

Cleveland, OH 44195

E-mail: kalliaa@ccf.org